AZD1390
AZD1390 (AZD-1390) is a novel potent, selective, orally available and CNS penetrant ATM inhibitor with IC50 of 0.78 nM, displays >1,000-fold selectivity over closely related (PIKKs) and distant kinases; radiosensitises a panel of glioblastoma multiforme (GBM) cell lines and NCI-H2228 lung cells (IC50=3 nM) ; demonstrates potential in combination with radiation therapy for the treatment of brain tumors.Brain Cancer, Phase 1 Clinical (In Vivo) :Median survival of mice treated with AZD1390 and radiation are significantly longer than untreated control mice (p=0.001) . No overt signs of treatment toxicity are observed with small animal radiation research platform (SARRP) contrary to wholehead irradiated mice that seem to develop mucositis and difficulties drinking and eating at doses >10 Gy in combination with AZD1390.
Product Specifications
CAS Number
2089288-03-7
Product Name Alternative
AZD 1390 | AZD-1390
Purity
>98% (HPLC)
Solubility
DMSO: 20 mg/mL, Need ultrasonic and warming (< 1 mg/ml refers to the product slightly soluble or insoluble)
Smiles
O=C (N1C (C) C) N (C) C2=C1C3=CC (C4=CC=C (OCCCN5CCCCC5) N=C4) =C (F) C=C3N=C2
Molecular Formula
C27H32FN5O2
Molecular Weight
477.584
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
2H-Imidazo[4,5-c]quinolin-2-one,7-fluoro-1,3-dihydro-3-methyl-1- (1-methylethyl) -8-[6-[3- (1-piperidinyl) propoxy]-3-pyridinyl]-
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
